Presentations & Posters
NKX101, an allogeneic off-the-shelf NKG2D CAR-NK cell therapy, has potent in vitro cytotoxicity against patient-derived AML leukemic stem cells and non-leukemic stem cell blasts
Poster Presentation | AACR | April 2024
NKX101, an allogeneic off-the-shelf CAR NK cell therapy targeting NKG2D-Ls, has potent anti-leukemic activity alone or in combination with Ara-C
Poster Presentation | AACR | April 2024
A Phase 1 Study of NKX101, A Chimeric Antigen Receptor Natural Killer (CAR-NK) Cell Therapy in Patients with Acute Myeloid Leukemia
Poster Presentation | ASH | December 2023
Differential Dependency of CD19 Chimeric Antigen Receptor (CAR)-T (TX019) and CD19- (CAR) Natural Killer (NK) Cells (NKX019) on CD58 Loss in Acute Lymphoblastic Leukemia (ALL)
Poster Presentation | NK2023 | September 2023
First in Human Data of NKX019, an Allogeneic CAR NK for the Treatment of Relapsed/Refractory (r/r) B-cell Malignancies
Poster Presentation | ICML | June 2023
First in Human Data of NKX019, an Allogeneic CAR NK for the Treatment of Relapsed/Refractory (r/r) B-cell Malignancies
Oral Presentation | EHA | June 2023
Combination of Anti-EGFR Antibody Cetuximab with NKX101, an Allogeneic NKG2D-L Targeting NK Cell Therapy, Enhances Potency and in vitro Cytoxcity Against Solid Tumors
Poster Presentation | AACR | April 2023
ADAM17 Knockout NK or CAR NK Cell Augment Antibody Dependent Cellular Cytotoxicity (ADCC) and Anti-Tumor Activity
Poster Presentation | AACR | April 2023
Large-Scale Expansion and Engineering of Human NK Cells Sourced from Peripheral Blood Versus Umbilical Cord Blood
Poster Presentation | SITC | November 2022
NKX019, an Off-the-Shelf CD19 CAR-NK Cell, Mediates Improved Anti-Tumor Activity and Persistence in Combination with CD20-Directed Therapeutic mAbs
Poster Presentation | SITC | November 2022
Development of Multi-omics Approaches to Evaluate NKG2D-ligand Dynamics and Anti-tumor Immune Responses during CAR-NK Treatment
Poster Presentation | AACR | April 2022
Immune Masking Strategies to Extend the Pharmacokinetics of Allogeneic Cell Therapies
Poster Presentation | AACR | April 2022
CBLB, CISH and CD70 Multiplexed Gene Knockout with CRISPR/Cas9 Enhances Cytotoxicity of CD70 CAR NK Cells and Provides Greater Resistance to TGF β for Cancer Immunotherapy
Poster Presentation | AACR | April 2022
Surveying Surface Antigens Expression in Multiple Myeloma Preclinical Models
Poster Presentation | AACR | April 2022
A Phase 1 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects with B-cell Malignancies
Poster Presentation | ASH | December 2021
A Combined Strategy of CD70 CAR Co-expression with Membrane-bound IL-15 and CISH Knockout Results in Enhanced NK Cytotoxicity and Persistence
Oral Presentation | SITC | November 2021
CISH Gene-knockout Anti-CD70-CAR NK Cells Demonstrate Potent Anti-tumor Activity Against Solid Tumor Cell Lines and Provide Partial Resistance to Tumor Microenvironment Inhibition
Poster Presentation | SITC | November 2021
Potentiating the Large-Scale Expansion and Engineering of Peripheral Blood-Derived CAR NK Cells for Off-the-Shelf Application
Poster Presentation | SITC | November 2021
KIR Haplotype Can Inform Donor Selection in the Production of Allogeneic Memory-Like CAR NK Cells for Clinical Application
Poster Presentation | SITC | November 2021
A Phase 1 Study of NKX101, an Allogeneic CAR Natural Killer (NK) Cell Therapy, in Subjects With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher Risk Myelodysplastic Syndrome (MDS)
Poster Presentation | ASH | December 2020
Preclinical evaluation of NKX019, a CD19-targeting NK cell
Poster Presentation | SITC | November 2020
A combination of CAR-NK and CAR-T cells results in rapid and persistent anti-tumor efficacy while reducing CAR-T cell mediated cytokine release and T-cell proliferation
Poster Presentation | AACR | June 2020
CRISPR-Cas9-gRNA RNP mediated gene knockout of TGFbR2 and CISH enhances CD19-CAR NK cell function and provides resistance to TGFb
Poster Presentation | AACR | June 2020
Co-expression of a CD19-OX40-CD3ζ CAR with membrane bound IL-15 enhances natural killer cell function
Poster Presentation | AACR | November 2019
Stimulatory cells plus IL-12 and IL-18 augments NK cell expansion, transduction, memory phenotype, and in vitro and in vivo CAR NK cytotoxicity & persistence
Poster Presentation | SITC | November 2019
Expanded and engineered NK cells for the treatment of hepatocellular carcinoma
Poster Presentation | AACR | July 2019
Expanded and engineered NK cells upregulate expression of activation and survival genes associated with increased cytotoxicity and persistence
Poster Presentation | AACR | March 2019
NK Cells Engineered to Express a Bispecific CD123/NKG2D Chimeric Antigen Receptor (CAR) and IL-15 As Off-the-Shelf Therapy for Acute Myeloid Leukemia
Poster Presentation | Keystone | March 2019
Co-expression of a chimeric NKG2D receptor with membrane bound IL-15 enhances natural killer cell function and long term persistence in vitro and in vivo
Poster Presentation | SITC | March 2018
Publications & References
Natural Killer Cells May Be Scaled and Engineered as a Next Generation, Off-the-Shelf Cell Therapy for Cancer
Cell & Gene Therapy Insights, Trager, October 2019
The Rise of Allogeneic Natural Killer Cells As a Platform for Cancer Immunotherapy: Recent Innovations and Future Developments
Front Immunol, Veluchamy et al, May 2017
Expanded and Activated Natural Killer Cells for Immunotherapy of Hepatocellular Carcinoma
Cancer Immunol Res , Kamiya, Chang, Campana, July 2016
Ex Vivo-Expanded Natural Killer Cells Demonstrate Robust Proliferation in Vivo in High-Risk Relapsed Multiple Myeloma Patients
J Immunother, Szmania et al, January 2015
Autonomous Growth and Increased Cytotoxicity of Natural Killer Cells Expressing Membrane-Bound interleukin-15
Blood, Imamura et al, August 2014
Clearance of Acute Myeloid Leukemia by Haploidentical Natural Killer Cells Is Improved Using IL-2 Diphtheria Toxin Fusion Protein
Blood, Bachanova et al, June 2014
A Chimeric Receptor With NKG2D Specificity Enhances Natural Killer Cell Activation and Killing of Tumor Cells
Cancer Res, Chang et al, March 2013
Natural Killer Cell Reprogramming With Chimeric Immune Receptors
Methods Mol Biol, Shimasaki, Campana, 2013
Cytotoxicity of Activated Natural Killer Cells Against Pediatric Solid Tumors
Clin Cancer Res, Cho et al, August 2010
Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells
Blood, Imai, Iwamoto, Campana, March 2008
perspectives
January 7, 2021
Statement on Political Violence and the Storming of the U.S Capitol
June 2, 2020
Message to Nkarta Employees on George Floyd and Ongoing Protests